Atrial Fibrillation trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Atrial Fibrillation. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month6 studies across 3 companies, in the next 180 days.
October 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BSX | Boston Scientific Corporation | cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-AsiaNCT06686485observationalPeriprocedural or procedure-related Composite Serious Adverse Events will be assessed | — | Recruiting | 2026-10-31 | in 72 d | 2026-07-23 |
| PLSE | Pulse Biosciences, Inc. | NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX SystemNCT07018596Proportion of participants with freedom from primary safety endpoint | Not applicable | Recruiting | Oct 2026 | ≤ 72 d | 2026-05-06 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PLSE | Pulse Biosciences, Inc. | CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial FibrillationNCT06355063Rate of acute major adverse events (MAEs) | Not applicable | Recruiting | 2026-12-31 | in 133 d | 2026-01-12 |
February 2027 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationNCT07175428Incidence of any bleeding | Phase 2 | Recruiting | 2027-02-09 | in 173 d | 2026-08-05 |
| BSX | Boston Scientific Corporation | Feasibility Study of the FARAFLEX Mapping and PFA SystemNCT06510556Device or procedure-related Composite Serious Adverse Events (CSAEs) | Not applicable | Recruiting | 2027-02-15 | in 179 d | 2026-07-27 |
| BSX | Boston Scientific Corporation | FARAPULSE Workflow Assessment RegistryNCT06656884observationalAssociation of patient demographics with Index procedure Workflow-related variables | — | Active, not recruiting | 2027-02-15 | in 179 d | 2026-07-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Atrial Fibrillation
most recently updated first205 studies match. Showing the first 100 of 205 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BSX | Boston Scientific Corporation | $73.1B | Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation SystemNCT05501873observationalPrimary Effectiveness Endpoint | — | Active, not recruiting | Device: FARAPULSE Pulsed Field Ablation system | Atrial Fibrillation | 1,173 | 2023-03-24 | 2025-10-21actual | — | 2026-08-19 |
| BSX | Boston Scientific Corporation | $73.1B | PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)NCT07106970Primary Effectiveness Endpoint with Treatment Success. | Not applicable | Recruiting | Procedure: Linear ablation, PVI alone | Persistent Atrial Fibrillation | 640 | 2025-08-28 | 2027-12-30 | in 497 d | 2026-08-17 |
| BSX | Boston Scientific Corporation | $73.1B | WATCHMAN FLX Pro European RegistryNCT07262255observationalNumber of participants with a safety event treated with the WATCHMAN FLX Pro | — | Recruiting | Device: Left atrial appendage closure | Non-valvular Atrial Fibrillation (AF), Left Atrial Appendage Closure | 1,000 | 2025-12-17 | Aug 2027 | ≤ 376 d | 2026-08-13 |
| BSX | Boston Scientific Corporation | $73.1B | CHAMPION-AF Clinical TrialNCT04394546WATCHMAN FLX is non-inferior (NI) for the occurrence of stroke, cardiovascular death, and systemic embolism | Not applicable | Active, not recruiting | Device: WATCHMAN FLX LAAC Device · Drug: Non-Vitamin K Oral Anticoagulant | Atrial Fibrillation, Stroke, Bleeding | 3,000 | 2020-10-15 | Dec 2027 | ≤ 498 d | 2026-08-12 |
| BSX | Boston Scientific Corporation | $73.1B | SIMPLAAFY Clinical TrialNCT06521463Reduced dose NOAC Arm Primary Endpoint: Composite rate of all death, all stroke, systemic embolism, and ISTH major bleeding at 6-months after randomization in the reduced dose NOAC arm tested for non-inferiority compared to the DAPT arm | Not applicable | Active, not recruiting | Device: WATCHMAN FLX Pro LAAC Device | Atrial Fibrillation, Stroke, Bleeding | 1,857 | 2024-10-01 | 2026-07-07actual | — | 2026-08-10 |
| ADGM | Adagio Medical | $14M | iCLAS™ for Persistent Atrial FibrillationNCT04061603results2026-08-06Analysis of the Proportion of Subjects Who Are Free From Device/Procedure Related Major Adverse Events (MAEs) That Occur Following the Cryoablation Procedure | Not applicable | Completed | Device: Adagio AF Cryoablation System (iCLAS™) | Persistent Atrial Fibrillation | 215 | 2019-12-09 | 2023-08-30actual | — | 2026-08-06 |
| BSX | Boston Scientific Corporation | $73.1B | Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial FibrillationNCT07575269Proportion of Treatment Subjects and Attempt Subjects with device- or procedure-related defined Composite Serious Adverse Events, assessed through Day 60 following the index procedure. | Not applicable | Recruiting | Device: FARAFLEX Mapping and Pulsed Field Ablation (PFA) System | Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation | 571 | 2026-07-07 | 2028-07-20 | in 700 d | 2026-08-06 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationNCT07175428Incidence of any bleeding | Phase 2 | Recruiting | Drug: REGN7508, REGN9933, Apixaban | Atrial Fibrillation (AF) | 1,200 | 2025-10-20 | 2027-02-09 | in 173 d | 2026-08-05 |
| BSX | Boston Scientific Corporation | $73.1B | OPTION-EMEA Clinical TrialNCT07349121Primary Safety Endpoint (PSE): Device or Procedure Related Serious Adverse Events | Not applicable | Recruiting | Device: Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional case · Procedure: Concomitant Pulsed Field Ablation and Left Atrial Appendage Closure | Atrial Fibrillation (AF), Stroke Prevention in Patients With Atrial Fibrillation, Left Atrial Appendage Closure, Pulsed Field Ablation, Atrial Fibrillation Ablation Procedure, Concomitant Procedures | 500 | 2026-06-18 | Dec 2028 | ≤ 864 d | 2026-08-05 |
| BSX | Boston Scientific Corporation | $73.1B | A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial FibrillationNCT07187115Primary Safety Endpoint | Not applicable | Active, not recruiting | Device: FARAPOINT Pulsed Field Ablation System, OptiMap System (non-ablative), FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System | Atrial Fibrillation (AF), Persistant Atrial Fibrillation | 699 | 2025-11-07 | Jul 2028 | ≤ 711 d | 2026-07-29 |
| BSX | Boston Scientific Corporation | $73.1B | FARAPULSE Workflow Assessment RegistryNCT06656884observationalAssociation of patient demographics with Index procedure Workflow-related variables | — | Active, not recruiting | — | Atrial Fibrillation (AF) | 524 | 2025-05-06 | 2027-02-15 | in 179 d | 2026-07-28 |
| BSX | Boston Scientific Corporation | $73.1B | A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial FibrillationNCT06808217observationalPrimary Safety Endpoint | — | Active, not recruiting | Device: FARAPULSE Pulsed Field Ablation System | Atrial Fibrillation, Pulsed Field Ablation, FARAPULSE | 550 | 2025-07-30 | 2027-04-01 | in 224 d | 2026-07-28 |
| BSX | Boston Scientific Corporation | $73.1B | Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial FibrillationNCT06096337Rate of randomized PFA or PFA Assigned subjects with PFA System inserted into the body, during the index or repeat PFA procedure during blanking period, with device or procedure-related Composite Adverse Events that is serious. | Not applicable | Active, not recruiting | Device: FARAPULSE™ Pulsed Field Ablation (PFA) System · Drug: Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone | Persistent Atrial Fibrillation | 484 | 2023-12-28 | 2026-02-04actual | — | 2026-07-27 |
| BSX | Boston Scientific Corporation | $73.1B | POLARx Post Approval Study (POLARx PAS)NCT06170606Percentage of Participants With Freedom From Primary Safety Events at 12 Months Post-procedure (Acute and Chronic Events) Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models | Not applicable | Completed | Device: Boston Scientific Cardiac Cryoablation System | Paroxysmal Atrial Fibrillation | 200 | 2024-06-28 | 2026-05-20actual | — | 2026-07-27 |
| BSX | Boston Scientific Corporation | $73.1B | ADVENT Post Approval StudyNCT06431815observationalComposite incidence of patients with procedure-related and device-related serious adverse events at 7-Days and 12-months post-Index Procedure. | — | Active, not recruiting | Device: FARAPULSE™ Pulsed Field Ablation System | Paroxysmal Atrial Fibrillation | 228 | 2024-09-25 | Oct 2028 | ≤ 803 d | 2026-07-27 |
| BSX | Boston Scientific Corporation | $73.1B | Feasibility Study of the FARAFLEX Mapping and PFA SystemNCT06510556Device or procedure-related Composite Serious Adverse Events (CSAEs) | Not applicable | Recruiting | Device: FARAFLEX Ablation Treatment, ELEVATE-COR Sub-study | Atrial Fibrillation, Persistent Atrial Fibrillation, Paroxysmal AF | 250 | 2025-02-17 | 2027-02-15 | in 179 d | 2026-07-27 |
| BSX | Boston Scientific Corporation | $73.1B | Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation SystemNCT06735534Primary safety endpoint rate | Not applicable | Recruiting | Device: FARAPULSE™ Pulsed Field Ablation System | Persistent Atrial Fibrillation | 376 | 2025-06-03 | Apr 2027 | ≤ 253 d | 2026-07-27 |
| BSX | Boston Scientific Corporation | $73.1B | Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA SystemNCT07444320Device or procedure-related Composite Adverse Events (CAEs) | Not applicable | Recruiting | Device: FARAPULSE™ Pulsed Field Ablation (PFA) System | Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation | 200 | 2026-02-12 | Feb 2028 | ≤ 558 d | 2026-07-27 |
| BSX | Boston Scientific Corporation | $73.1B | cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-AsiaNCT06686485observationalPeriprocedural or procedure-related Composite Serious Adverse Events will be assessed | — | Recruiting | Device: FARAPULSE™ PFA system and WATCHMAN LAAC Delivery Systems | Concomitant Procedures, Atrial Fibrillation, PFA, LAAC | 433 | 2025-03-18 | 2026-10-31 | in 72 d | 2026-07-23 |
| BEAT | HeartBeam, Inc. | $27M | HeartBeam ECG RegistryNCT07501299observationalCreation of a de-identified ECG dataset for future research and regulatory use | — | Recruiting | Diagnostic test: Electrocardiogram (ECG) | Atrial Fibrillation, Atrial Flutter, Bradycardia, Tachycardia, Arrhythmia | 600 | 2026-03-30 | Dec 2028 | ≤ 864 d | 2026-07-20 |
| PFE | Pfizer | $155.3B | High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in FranceNCT05038228observationalBleeding leading to hospitalization | — | Completed | Drug: Apixaban, Rivaroxaban, Dabigatran, Vitamin K antagonist (VKA) | Atrial Fibrillation | 1 | 2022-08-01 | 2026-05-29actual | — | 2026-06-30 |
| ATRC | AtriCure, Inc. | $2.3B | Tracking Results of Ablations to Combat AF Registry Generation 2NCT05111015observationalPatient's AF burden 6-month after receiving the ablation procedure | — | Recruiting | Device: Open Concomitant Surgical Ablation Procedures, Hybrid (Convergent) Ablation Procedures, AtriCure Hybrid Totally Thoracoscopic Ablation Procedures, AtriCure LAA Exclusion Procedures | Atrial Fibrillation | 10,000 | 2024-03-11 | Jan 2040 | ≤ 4,912 d | 2026-06-29 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitableNCT07430956Time to first occurrence of ischemic stroke or systemic embolism | Phase 3 | Recruiting | Drug: REGN7508, REGN9933, Placebo | Atrial Fibrillation (AF) | 2,628 | 2026-04-03 | 2029-03-28 | in 951 d | 2026-06-23 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationNCT07626411Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolism | Phase 3 | Not yet recruiting | Drug: REGN7508, Apixaban, Placebo | Atrial Fibrillation (AF) | 15,364 | 2026-07-31 | 2029-09-11 | in 1,118 d | 2026-06-04 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial FibrillationNCT05232643observationalAnticoagulant (OA) cohort: Distribution of participants starting any type of anticoagulant direct-acting oral anticoagulant (DOAC) or Vitamin K antagonist (VKA) treatment | — | Completed | — | Non-Valvular Atrial Fibrillation (NVAF) | 636 | 2020-07-09 | 2025-11-30actual | — | 2026-06-02 |
| PLSE | Pulse Biosciences, Inc. | $3.3B | NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX SystemNCT07018596Proportion of participants with freedom from primary safety endpoint | Not applicable | Recruiting | Device: CellFX nsPFA Cardiac Catheter System | Atrial Fibrillation Paroxysmal, Cardiac Ablation, Cardiac Arrhythmia | 215 | 2026-04-06 | Oct 2026 | ≤ 72 d | 2026-05-06 |
| PLSE | Pulse Biosciences, Inc. | $3.3B | CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial FibrillationNCT06696170Rate of primary safety major adverse events (MAEs) | Not applicable | Recruiting | Device: CellFX nano-pFA 360 Endocardial Ablation Catheter System | Atrial Fibrillation Paroxysmal, Cardiac Ablation, Cardiac Arrhythmia | 60 | 2024-07-25 | 2026-06-25 | — | 2026-05-05 |
| ADGM | Adagio Medical | $14M | Pulsed Field Ablation and Pulsed Field CRyoAbLation in PErsistent AtriaL FibrilLationNCT05408754Primary Endpoint for Safety | Not applicable | Completed | Device: Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF. | Atrial Fibrillation | 89 | 2022-10-20 | 2024-10-14actual | — | 2026-04-13 |
| ADGM | Adagio Medical | $14M | iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) StudyNCT05416086Primary outcome - freedom from AF | Not applicable | Terminatedsponsor's stated reason: Adagio Medical no longer manufactures the iCLAS Cryoablation System | Device: cryoablation procedure using the iCLAS Cryoablation System | Atrial Fibrillation, Atrial Flutter, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation | 91 | 2021-09-03 | 2025-01-28actual | — | 2026-04-13 |
| BSX | Boston Scientific Corporation | $73.1B | ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression StudyNCT06526546observationalChronic success in ADVENT Trial treated subjects compared between treatment groups. | — | Completed | — | Paroxysmal Atrial Fibrillation | 364 | 2024-10-31 | 2025-12-08actual | — | 2026-03-02 |
| BSX | Boston Scientific Corporation | $73.1B | Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial FibrillationNCT03729830results2026-01-21observationalNumber of Participants Safety Event-free at 12 Months Post Procedure | — | Completed | Device: Boston Scientific Open Irrigated Ablation Catheters | Paroxysmal Atrial Fibrillation | 415 | 2019-03-04 | 2024-05-03actual | — | 2026-01-21 |
| PLSE | Pulse Biosciences, Inc. | $3.3B | CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial FibrillationNCT06355063Rate of acute major adverse events (MAEs) | Not applicable | Recruiting | Device: CellFX® nsPFA™ Cardiac Surgery System | Atrial Fibrillation, Surgery, Ablation of Atrial Fibrillation, Clamp Study | 30 | 2024-07-31 | 2026-12-31 | in 133 d | 2026-01-12 |
| PLSE | Pulse Biosciences, Inc. | $3.3B | CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial FibrillationNCT06959121Freedom from atrial fibrillation/atrial flutter/atrial tachycardia | Not applicable | Recruiting | Device: CellFX® nsPFA™ Cardiac Surgery System | Atrial Fibrillation, Maze Procedure, AF, Ablation | 135 | 2025-10-23 | Apr 2027 | ≤ 253 d | 2026-01-12 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in FranceNCT05838664results2025-12-24observationalIncidence Rate (Per 1000 Participant-years) of Stroke in Non-valvular Atrial Fibrillation (AF) Participants Exposed to Oral Anticoagulation (OAC) and Unexposed to OAC | — | Completed | Drug: No OAC, VKA, apixaban, rivaroxaban, dabigatran | Atrial Fibrillation | 2,140,403 | 2023-07-07 | 2024-09-30actual | — | 2025-12-24 |
| BSX | Boston Scientific Corporation | $73.1B | A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial FibrillationNCT05443594results2025-10-24Primary Safety Endpoint (PSE): Event Rate of Safety Events Post Procedure | Not applicable | Completed | Device: Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System | Persistent Atrial Fibrillation | 669 | 2023-02-28 | 2025-02-11actual | — | 2025-12-16 |
| BSX | Boston Scientific Corporation | $73.1B | Watchman FLX Pro CT Pilot StudyNCT05567172results2025-12-09Number of Participants With Any Hypoattenuated Thickening (HAT) on the Surface of the Device | Not applicable | Completed | Device: Left atrial appendage closure device WM FLX Pro | Non-valvular Atrial Fibrillation (AF) | 43 | 2023-03-24 | 2024-10-14actual | — | 2025-12-09 |
| BSX | Boston Scientific Corporation | $73.1B | POLARx™ Cardiac Cryoablation System Post Market Clinical Study (POLAR SMART)NCT05282823results2025-12-02observationalSafety Event Free Rate | — | Completed | Device: Boston Scientific Cardiac Cryoablation System | Paroxysmal Atrial Fibrillation | 295 | 2022-08-26 | 2024-10-29actual | — | 2025-12-02 |
| PFE | Pfizer | $155.3B | Atrial Fibrillation Data Linkage Non-Interventional StudyNCT05810727observationalEvent Rate of Stroke/Systemic embolism (SE) | — | Completed | — | Atrial Fibrillation | 12,556 | 2025-08-21 | 2025-10-23actual | — | 2025-11-20 |
| BSX | Boston Scientific Corporation | $73.1B | HEAL-LAA Clinical TrialNCT05809596results2025-10-15Primary Efficacy Endpoint: The Rate of Device Leak >5 mm at 45-day Post-Implant TEE for the Primary Analysis Subjects | Not applicable | Completed | Device: WATCHMAN FLX Pro LAAC Device | Atrial Fibrillation, Bleeding, Stroke | 949 | 2023-10-03 | 2024-07-15actual | — | 2025-11-04 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial FibrillationNCT05804747observationalNumber of Participants With Composite of Stroke, Systemic Embolic Events, Major Bleeding, or All-Cause Mortality | — | Completed | Drug: Edoxaban | Atrial Fibrillation | 1,204 | 2023-02-16 | 2025-07-28actual | — | 2025-09-26 |
| BSX | Boston Scientific Corporation | $73.1B | Comparison of Anticoagulation With Left Atrial Appendage Closure After AF AblationNCT03795298results2025-09-18Primary Effectiveness Endpoint: Stroke, All Cause Death, and Systemic Embolism | Not applicable | Completed | Device: WATCHMAN FLX Implant · Drug: Market-approved OAC | Atrial Fibrillation | 1,600 | 2019-05-20 | 2024-07-24actual | — | 2025-09-18 |
| BSX | Boston Scientific Corporation | $73.1B | Feasibility Study on the FARAVIEW TechnologyNCT06175234Number of subjects with PVI success | Not applicable | Completed | Device: Ablation Treatment | Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation | 50 | 2024-04-03 | 2025-05-15actual | — | 2025-09-17 |
| BMY | Bristol-Myers Squibb | $134.9B | Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial FibrillationNCT03087487observationalTime to first major bleeding event | — | Completed | — | Non-Valvular Atrial Fibrillation | 466,991 | 2016-06-01 | 2023-02-26actual | — | 2025-06-25 |
| BSX | Boston Scientific Corporation | $73.1B | Cryoablation System FIM/CE Mark StudyNCT03723070results2021-07-19Primary Safety Outcome: Percentage of Participants With Procedure Related Adverse Events OR Device Related Adverse Events OR Serious Adverse Device Effects | Not applicable | Completed | Device: The Cryterion Cardiac Cryoablation System | Atrial Fibrillation | 88 | 2018-05-15 | 2020-12-22actual | — | 2025-04-04 |
| BSX | Boston Scientific Corporation | $73.1B | POLARx Cardiac Cryoablation System StudyNCT04250714results2024-02-12observationalSafety Event Free Rate | — | Completed | Device: Boston Scientific Cardiac Cryoablation System | Atrial Fibrillation | 400 | 2020-08-06 | 2022-09-26actual | — | 2025-04-04 |
| BSX | Boston Scientific Corporation | $73.1B | Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial FibrillationNCT04133168results2023-12-07Percentage of Participants With Freedom From Primary Safety Events at 12 Months Post-procedure (Acute and Chronic Events) Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models | Not applicable | Completed | Device: Boston Scientific Cardiac Cryoablation System | Paroxysmal Atrial Fibrillation | 458 | 2020-06-24 | 2022-11-10actual | — | 2025-04-03 |
| PFE | Pfizer | $155.3B | Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In ColombiaNCT04234698results2025-02-06observationalTime to Diagnose NVAF by Each OAC Treatment | — | Completed | — | Atrial Fibrillation | 2,076 | 2021-03-22 | 2021-10-31actual | — | 2025-02-06 |
| BSX | Boston Scientific Corporation | $73.1B | A RWS of the FARAPULSE in A Chinese Population With PAFNCT05493852results2024-12-16observationalNumber of Participants With Acute Procedural Success | — | Completed | Device: FARAPULSE Pulsed Field Ablation System | Paroxysmal Atrial Fibrillation | 30 | 2023-02-24 | 2023-08-21actual | — | 2025-01-31 |
| BSX | Boston Scientific Corporation | $73.1B | Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial FibrillationNCT04580914results2025-01-16Rate of Primary Safety Events at 1-Month Post-Procedure | Not applicable | Completed | Device: Treatment with IntellaNav StablePoint Ablation Catheter | Paroxysmal Atrial Fibrillation | 321 | 2021-04-12 | 2023-06-21actual | — | 2025-01-16 |
| ATRC | AtriCure, Inc. | $2.3B | FREEZE-AFIB Post-Market StudyNCT05089877results2025-01-13observationalFreedom From Death, Stroke (Regardless of Level of Disability), Myocardial Infarction, and Major Bleeding Events. | — | Completed | Device: Surgical Ablation | Atrial Fibrillation, Atrial Flutter | 39 | 2022-04-29 | 2023-03-31actual | — | 2025-01-13 |
| 4568.T | Daiichi Sankyo | $31.7B | Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in ChinaNCT04747496observationalIncidence (including 95% confidence intervals) of major bleeding events following edoxaban treatment | — | Completed | Drug: Edoxaban | Non-valvular Atrial Fibrillation | 5,000 | 2021-02-26 | 2024-11-27actual | — | 2025-01-09 |
| BSX | Boston Scientific Corporation | $73.1B | The FARAPULSE PersAFOne III Trial for the Treatment of Persistent Atrial FibrillationNCT05272852results2025-01-08Primary Safety Endpoint: Composite Safety Endpoint (CSE) Defined as the Incidence of the Following Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are Device- or Procedure-related, as Adjudicated by the CEDMC | Not applicable | Completed | Device: FARAPULSE™ Pulsed Field Ablation System Plus | Persistent Atrial Fibrillation | 80 | 2022-02-03 | 2024-02-09actual | — | 2025-01-08 |
| ATRC | AtriCure, Inc. | $2.3B | Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) ApproachNCT02393885results2024-12-19Primary Effectiveness Endpoint | Not applicable | Completed | Device: AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation | Atrial Fibrillation, Persistent or Longstanding Persistent Atrial Fibrillation | 90 | Feb 2015 | 2022-03-28actual | — | 2024-12-19 |
| BSX | Boston Scientific Corporation | $73.1B | LUX-Dx Insertable Cardiac Monitor Remote Programming and Performance StudyNCT04732728results2024-11-25observationalICM System-related Complication-free Rate at 30 Days Post-implant | — | Completed | — | Atrial Fibrillation, Syncope, Cryptogenic Stroke | 727 | 2021-03-05 | 2023-05-18actual | — | 2024-11-25 |
| BSX | Boston Scientific Corporation | $73.1B | The FARAPULSE ADVENT PIVOTAL Trial PFA System vs SOC Ablation for Paroxysmal Atrial FibrillationNCT04612244results2024-11-20Composite Safety Endpoint;Proportion of MITT Subjects With One or More of the Specified Device or Procedure Related SAEs | Not applicable | Completed | Device: FARAPULSE Pulsed Field Ablation System, RadioFrequency and Cryoballoon Ablation | Paroxysmal Atrial Fibrillation | 706 | 2021-03-01 | 2023-05-15actual | — | 2024-11-20 |
| BSX | Boston Scientific Corporation | $73.1B | The FARAPULSE FARA-Freedom TrialNCT05072964results2024-10-17Effectiveness: Percentage of Participants Free of Chronic Treatment Failure Through 12 Months and Freedom From Recurrence of Symptomatic Atrial Fibrillation, Atrial Tachycardia or Atrial Flutter | Not applicable | Completed | Device: FARAPULSE Pulsed Field Ablation System | Paroxysmal Atrial Fibrillation | 180 | 2021-12-21 | 2023-10-12actual | — | 2024-10-17 |
| ATRC | AtriCure, Inc. | $2.3B | Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial FibrillationNCT02695277Number of subjects free from documented Atrial Fibrillation (AF), Atrial Flutter (AFL) or Atrial Tachycardia (AT) episodes > 30 seconds in duration through 12 months follow-up, in the absence of Class I or III Antiarrhythmic Drugs (AADs). | Not applicable | Completed | Device: AtriCure Bipolar System, Standard Endocardial Ablation with Catheter, AtriClip® PRO LAA Exclusion System, Endocardial Ablation with Catheter, Repeated Endocardial ablation(s) | Atrial Fibrillation, Persistent and Longstanding Persistent Atrial Fibrillation | 146 | Nov 2015 | Nov 2022actual | — | 2024-10-15 |
| ATRC | AtriCure, Inc. | $2.3B | AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation TreatmentNCT03732794Primary Effectiveness Endpoint: Freedom from AF/Atrial Flutter (AFL)/Atrial Tachycardia (AT) | Not applicable | Active, not recruiting | Device: AtriCure CryoICE & AtriClip LAA Exclusion | Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation | 150 | 2019-01-30 | 2024-06-27actual | — | 2024-10-15 |
| BSX | Boston Scientific Corporation | $73.1B | Observe the Safety and Effectiveness of the WATCHMAN FLX™ for Subjects in Hong KongNCT04096963results2024-08-12observationalPrimary Effectiveness Endpoint | — | Completed | Device: The WATCHMAN FLX Delivery System | Non-valvular Atrial Fibrillation | 50 | 2020-06-19 | 2022-01-24actual | — | 2024-08-12 |
| TEM | Tempus AI | $8.6B | Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart DiseaseNCT05442203Positive-predictive value (PPV) of the AF device at six months | Not applicable | Unknown status | Device: Zio Patch Monitor, Echocardiogram | Atrial Fibrillation, Structural Heart Disease | 1,000 | 2022-09-07 | Jul 2025 | — | 2024-07-25 |
| PFE | Pfizer | $155.3B | Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of BleedingNCT05471505results2024-07-11observationalIncidence Rate Per 1000 Participant-Years For First Occurrence of Composite Stroke and Systemic Embolism (SE) Events After Index Date: Balanced Cohorts | — | Completed | — | Non-valvular Atrial Fibrillation | 120,722 | 2022-08-25 | 2022-09-27actual | — | 2024-07-11 |
| BEAT | HeartBeam, Inc. | $27M | AIMIGo 12L ECG Synthesis Software Pivotal Study for Arrythmia DetectionNCT06123130Clinical equivalence of ECG intervals compared between AIMIGo Synthesized 12L and reference standard 12L | Not applicable | Completed | Device: Vectorcardiography (VECG) | Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Flutter, Bradycardia, Tachycardia | 198 | 2024-03-13 | 2024-06-20actual | — | 2024-07-05 |
| BMY | Bristol-Myers Squibb | $134.9B | DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial FibrillationNCT05838781Incident AF | Not applicable | Completed | Diagnostic test: Risk prediction model, 14-days continuous ECG monitoring | Atrial Fibrillation, Atrial Flutter | 2,112 | 2023-12-04 | 2024-05-16actual | — | 2024-05-22 |
| PFE | Pfizer | $155.3B | Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims DataNCT05438888results2024-05-20observationalIncidence Rate (Per 1,000 Participant-Year) of Composite of Stroke and Systemic Embolism (SE): Balanced Cohorts | — | Completed | Drug: Warfarin, Apixaban | Non-valvular Atrial Fibrillation | 77,814 | 2022-07-01 | 2022-10-19actual | — | 2024-05-20 |
| ABBV | AbbVie | $457.5B | Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)NCT03779841results2024-05-14Percentage of Participants With at Least 1 Continuous AF (Atrial Fibrillation or Atrial Flutter) Episode ≥ 30 Seconds During the First 30 Days Post-surgery | Phase 2 | Completed | Drug: AGN-151607, Placebo | Post-Operative Atrial Fibrillation | 323 | 2019-03-01 | 2022-03-24actual | — | 2024-05-14 |
| ATRC | AtriCure, Inc. | $2.3B | aMAZE Trial Continued Access ProtocolNCT04468334Freedom from episodes of atrial fibrillation > 30 seconds at 12 months post index pulmonary vein isolation | Not applicable | Completed | Device: LARIAT + PVI | Atrial Fibrillation | 82 | 2020-03-09 | 2023-04-24actual | — | 2024-03-12 |
| BSX | Boston Scientific Corporation | $73.1B | Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II)NCT05152966results2024-01-31Composite Safety Endpoint;Proportion of Intent to Treat Subjects With One or More of the Specified Device or Procedure Related SAEs | Not applicable | Completed | Device: Ablation | Persistent Atrial Fibrillation | 20 | 2021-09-16 | 2022-12-01actual | — | 2024-02-28 |
| BSX | Boston Scientific Corporation | $73.1B | Feasibility Study of the FARAPULSE Endocardial Multi Ablation System in the Treatment of Persistent Atrial FibrillationNCT04170621results2024-01-30Safety at 30 Days | Not applicable | Completed | Device: Ablation | Persistent Atrial Fibrillation | 28 | 2019-10-18 | 2021-07-14actual | — | 2024-01-30 |
| PFE | Pfizer | $155.3B | Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial FibrillationNCT05321810results2024-01-11observationalIncidence Rate of a Composite of Recurrent Stroke or Systemic Embolism (SE) During the Follow-up Period: Secondary Prevention (Balanced) Cohort | — | Completed | Drug: Apixaban, Warfarin | Non-valvular Atrial Fibrillation | 193,565 | 2022-04-15 | 2022-04-15actual | — | 2024-01-11 |
| SNY | Sanofi | — | Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial FibrillationNCT05279833observationalNumber of participants with Cardiovascular (CV) hospitalization | — | Completed | Drug: dronedarone, sotalol | Atrial Fibrillation | 87,810 | 2021-09-24 | 2022-03-31actual | — | 2024-01-09 |
| BMY | Bristol-Myers Squibb | $134.9B | Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using PacemakersNCT02153437The effect of BMS-919373 on Atrial effective refractory period (AERP) in subjects with a dual chamber pacemaker | Phase 1 | Terminated | Drug: BMS-919373, Sotalol, Placebo for BMS-919373 | Atrial Fibrillation | 7 | 2014-10-30 | 2016-10-20actual | — | 2023-12-19 |
| ATRC | AtriCure, Inc. | $2.3B | CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)NCT01984346results2022-02-10Primary Efficacy Endpoint - Number of Participants to Achieve Freedom From AF/AT/AFL. | Not applicable | Completed | Device: AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax, Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering | Persistent Atrial Fibrillation | 170 | Dec 2013 | Aug 2019actual | — | 2023-11-13 |
| 4568.T | Daiichi Sankyo | $31.7B | Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary InterventionNCT04519944observationalUsage of Peri- and Post-procedural Anticoagulation and Antiplatelet Therapy in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | — | Completed | Drug: Edoxaban | Non-valvular Atrial Fibrillation | 666 | 2020-06-30 | 2023-07-06actual | — | 2023-08-02 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of StrokeNCT04126486Incidence of all strokes leading to hospitalization | Phase 4 | Completed | Other: Zio®XT Monitor | Atrial Fibrillation, Atrial Flutter | 11,931 | 2019-12-17 | 2023-06-30actual | — | 2023-07-12 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF)NCT05044533observationalDistribution of characteristics of AF participants: Quality of life (QoL) data | — | Completed | — | Atrial Fibrillation | 50 | 2021-05-31 | 2022-03-09actual | — | 2023-06-18 |
| PFE | Pfizer | $155.3B | Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)NCT03441633results2019-04-19observationalNumber of Participants by Their Sociodemographic Characteristics: Smoking Habit | — | Completed | Drug: apixaban, dabigatran, VKA, rivaroxaban | Atrial Fibrillation | 51,690 | 2016-02-18 | 2017-03-08actual | — | 2023-06-09 |
| PFE | Pfizer | $155.3B | Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With MedicareNCT04681482results2021-12-06observationalEvent Rate Per 100 Participant-Years For First Occurrence of Major Bleeding Events After Index Date in Obese Participants | — | Completed | Drug: Apixaban | Atrial Fibrillation, Obesity, Anticoagulants | 107,383 | 2020-11-02 | 2020-11-03actual | — | 2023-05-22 |
| PFE | Pfizer | $155.3B | Assessment of the Effectiveness and Safety Outcome in Patients With Atrial Fibrillation Treated by Apixaban in BelgiumNCT05116267observationalEvent Rate of Stroke/Systemic Embolism Requiring Hospitalization: Apixaban treated patients | — | Withdrawnsponsor's stated reason: Protocol is not feasible based on the available hospital records | — | Atrial Fibrillation | 0 | 2021-10-01 | 2022-12-31 | — | 2023-05-17 |
| BSX | Boston Scientific Corporation | $73.1B | Electrical Coupling Information From The RHYTHMIA HDx Mapping System and DIRECTSENSE Technology In The Treatment of Paroxysmal Atrial Fibrillation (LOCALIZE CF)NCT04740801Association between Local Impedance drop values and PV reconnections | Not applicable | Completed | Device: Ablation procedure | Paroxysmal Atrial Fibrillation | 60 | 2021-06-28 | 2022-07-21actual | — | 2023-05-11 |
| BSX | Boston Scientific Corporation | $73.1B | A Single Arm Pilot Study of Pulsed Field Ablation in the Treatment of Paroxysmal Atrial FibrillationNCT04474054results2023-04-21Occurence of Device-or Procedure-related Early and Late-onset of Serious Adverse Events | Not applicable | Completed | Device: Catheter ablation to treat paroxysmal atrial fibrillation | Paroxysmal Atrial Fibrillation | 15 | 2020-07-07 | 2021-12-21actual | — | 2023-04-21 |
| PFE | Pfizer | $155.3B | Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in KoreaNCT03572972results2020-02-12observationalEvent Rate of Stroke/Systemic Embolism Requiring Hospitalization: NOAC Versus Warfarin Analysis | — | Completed | Drug: Apixaban, Dabigatran, Rivaroxaban, warfarin, Antiplatelets | Atrial Fibrillation | 64,684 | 2018-01-31 | 2018-12-20actual | — | 2023-04-06 |
| PFE | Pfizer | $155.3B | Non-Interventional Study Describing Direct Costs Related to Anti-coagulation TreatmentNCT04435769results2023-02-08observationalCHA2-DS2-VASc Score at Baseline | — | Completed | — | Atrial Fibrillation | 109 | 2020-08-04 | 2021-05-31actual | — | 2023-02-08 |
| AAPL | Apple Inc. | $4.52T | Atrial Fibrillation Algorithms Clinical Validation StudyNCT04699812results2022-08-24SENSITIVITY OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF] | Not applicable | Completed | Device: ELECTROCARDIOGRAM (ECG) PATCH WEAR | Atrial Fibrillation | 573 | 2020-11-16 | 2021-04-19actual | — | 2022-08-24 |
| ATRC | AtriCure, Inc. | $2.3B | CONVERGE CAP Study-For The Treatment Of Symptomatic Persistent or Long-standing Persistent AFNCT04239534Primary Effectiveness Endpoint- Freedom from Atrial Fibrillation, Atrial Tachycardia and Atrial Flutter | Not applicable | Withdrawnsponsor's stated reason: Start-up and enrolling activities have been suspended and study closed | Device: Convergence Of Epicardial And Endocardial RF Ablation | Atrial Fibrillation | 0 | Dec 2021 | Dec 2023 | — | 2022-07-27 |
| BMY | Bristol-Myers Squibb | $134.9B | Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)NCT03508258observationalIncidence of major bleeding | — | Withdrawnsponsor's stated reason: Study was discontinued in 2018 as sufficient sample size was not met. | Other: Non-interventional, Non-Interventional | Non-valvular Atrial Fibrillation | 0 | 2017-09-01 | 2018-09-01actual | — | 2022-06-30 |
| BSX | Boston Scientific Corporation | $73.1B | MODULA Modul 7 VRRNCT00180414results2022-03-29Percentage of Biventricular Pacing | Not applicable | Terminatedsponsor's stated reason: low enrolment rate | Device: CRT devices with ventricular rate regulation [VRR] (CE labeled) | Atrial Fibrillation | 8 | 2004-08-28 | 2008-05-07actual | — | 2022-06-24 |
| BSX | Boston Scientific Corporation | $73.1B | Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure TechnologyNCT02702271results2022-06-14Number of Participants With a Safety Event | Not applicable | Completed | Device: WATCHMAN FLX | Atrial Fibrillation | 458 | 2018-05-07 | 2020-01-28actual | — | 2022-06-14 |
| BSX | Boston Scientific Corporation | $73.1B | Data Collection Atrial Fibrillation Exploratory StudyNCT03647085observationalPhysiologic Signal Detection | — | Terminatedsponsor's stated reason: Due to COVID-19 and resourcing challenges | Device: Wearable cardiac monitor | Atrial Fibrillation, Atrial Flutter | 27 | 2018-08-29 | 2019-01-10actual | — | 2022-06-09 |
| BMY | Bristol-Myers Squibb | $134.9B | Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial FibrillationNCT02007655observationalIncidence rate of unexpected adverse events | — | Completed | Drug: Eliquis | NonValvular Atrial Fibrillation | 6,372 | 2013-09-01 | 2016-08-31actual | — | 2022-06-07 |
| 4568.T | Daiichi Sankyo | $31.7B | Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial FibrillationNCT02944019observationalPercentage of Participants Experiencing Real-World Safety Data Events within 4 Years | — | Completed | Drug: Edoxaban | Atrial Fibrillation | 13,980 | Aug 2015 | 2022-04-13actual | — | 2022-06-01 |
| BMY | Bristol-Myers Squibb | $134.9B | Evaluation of Safety and Effectiveness on Oral AnticoagulantsNCT03765242observationalIncidence of major bleeding among oral anticoagulant (OAC) initiators | — | Completed | Other: Non-Interventional | Atrial Fibrillation | 12,354 | 2018-09-21 | 2020-12-25actual | — | 2022-05-13 |
| BMY | Bristol-Myers Squibb | $134.9B | Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral AnticoagulantsNCT02754154observationalTime to "First Major" Bleeding event | — | Completed | Drug: Warfarin, Apixaban, Dabigatran, Rivaroxaban | Atrial Fibrillation | 321,182 | 2014-12-31 | 2018-12-26actual | — | 2022-05-09 |
| BSX | Boston Scientific Corporation | $73.1B | A Safety and Feasibility Study of the FARAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial FibrillationNCT03714178results2022-05-04The Primary Safety Endpoint for This Study is the Composite Safety Endpoint (CSE) Defined as the Proportion of Patients With Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are Device- or Procedure-related. | Not applicable | Completed | Device: FARAPULSE Endocardial Ablation System | Paroxysmal Atrial Fibrillation | 71 | 2018-10-20 | 2020-12-21actual | — | 2022-05-04 |
| BSX | Boston Scientific Corporation | $73.1B | PEFCATII Expanded Safety and Feasibility Study of the FARAPULSE Endocardial Multi Ablation System to Treat Paroxysmal Atrial FibrillationNCT04170608results2022-05-04Safety: Number of Participants With Prespecified Primary Safety Events Within 30 Days of Index Procedure. | Not applicable | Completed | Device: FARAPULSE Endocardial Multi Ablation System | Paroxysmal Atrial Fibrillation | 10 | 2019-10-18 | 2020-12-07actual | — | 2022-05-04 |
| BSX | Boston Scientific Corporation | $73.1B | WATCHMAN for Concomitant Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation RhythmNCT03835338Freedom from AF | Not applicable | Withdrawnsponsor's stated reason: Sponsor discretion | Device: Pulmonary Vein Isolation, LAA Isolation, LAA Occlusion | Persistent Atrial Fibrillation | 0 | 2021-09-01 | 2023-04-30 | — | 2022-03-31 |
| BSX | Boston Scientific Corporation | $73.1B | Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure TechnologyNCT01760291results2021-11-24Number of Participants With Ischemic Stroke | Not applicable | Completed | Device: WATCHMAN LAA Closure Technology | Atrial Fibrillation | 576 | Sep 2012 | Apr 2019actual | — | 2022-03-29 |
| 4568.T | Daiichi Sankyo | $31.7B | Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)NCT02943785results2022-03-24Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA | Phase 3 | Completed | Drug: Edoxaban-based Regimen, VKA-based Regimen | Atrial Fibrillation | 1,426 | 2017-03-21 | 2021-02-28actual | — | 2022-03-24 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in JapanNCT05027061observationalSpecialization of the treating physician | — | Completed | — | Non-Valvular Atrial Fibrillation (NVAF) | 11,776 | 2021-04-02 | 2021-12-04actual | — | 2022-03-17 |
| ATRC | AtriCure, Inc. | $2.3B | AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)NCT02701062results2021-11-24Number of Perioperative Complications Associated With AtriClip Placement | Phase 4 | Completed | Device: AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems · Drug: Anticoagulation Therapy | Post-Operative Atrial Fibrillation | 562 | Feb 2016 | 2019-04-26actual | — | 2021-11-24 |
| BSX | Boston Scientific Corporation | $73.1B | Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only)NCT02654470observationalprocedural success | — | Completed | Device: Watchman FLX | Non-valvular Atrial Fibrillation | 300 | 2019-07-16 | 2021-09-28actual | — | 2021-11-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Atrial Fibrillation is matched — 13 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Atrial Fibrillation
- Paroxysmal Atrial Fibrillation
- Persistent Atrial Fibrillation
- Non-valvular Atrial Fibrillation
- Atrial Fibrillation (AF)
- Longstanding Persistent Atrial Fibrillation
- Atrial Fibrillation Paroxysmal
- Non-Valvular Atrial Fibrillation (NVAF)
- Non-valvular Atrial Fibrillation (AF)
- NonValvular Atrial Fibrillation
- Paroxysmal Atrial Fibrillation (PAF)
- Post-Operative Atrial Fibrillation
- Stroke Prevention in Patients With Atrial Fibrillation
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Atrial Fibrillation” (a text search, wider than this page)